EXACT Sciences — FY2018 Earnings Presentation
34 slides from EXACT Sciences's earnings presentation, Jan 7, 2019
Slide 1: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections.
Slide 2: Preliminary fourth-quarter and full-year 2018 results
Preliminary fourth-quarter and full-year 2018 results Q4 2018 Revenue $142.5 - $143.5M (64% YoY) $454 - $455M (71% YoY) Completed tests 292,000 (66% YoY) 934,000 (64% YoY) New providers 15,000 45,000 FY 2018 Unaudited financial results
Slide 3: We deliver life-changing innovations in earlier cancer detection
We deliver life-changing innovations in earlier cancer detection 4 EXACT SCIENCES
Slide 4: Colorectal cancer: America's second deadliest cancer
Source: American Cancer Society, Cancer Facts & Figures 2018; all figures annual 50,630 Annual deaths Colorectal cancer: America’s second deadliest cancer Prostate Liver Breast Pancreatic Colorectal Lung
Slide 5: Detecting colorectal cancer early is critical
9 of 10 Survive 5 years Diagnosed in Stages I or II 1 of 10 Survive 5 years Diagnosed in Stage IV Source: SEER 18 2004-2010 – colorectal cancer statistics Detecting colorectal cancer early is critical
Slide 6: Cologuard: addressing the colorectal cancer challenge
Easy to use Non-invasive Developed with 94% Early-stage cancer sensitivity* For adults 50 years or older and at average risk No preparation No sedation No time off work 24/7 customer support *For stage I and II cancers; 92% sensitivity overall, 87% specificity Source: Imperiale TF et al., N Engl J M
Slide 7: Increasing America's screening population
Screening history of Cologuard users: Exact Sciences Laboratories patient satisfaction survey, Oct. 2017-Sep. 2018, n = 5,377 Note: excludes prior users of Cologuard 40% screened with colonoscopy 12% screened only with FIT/FOBT 48% never screened before Increasing America’s screening population Scre
Slide 8: Capturing a multi-billion dollar U.S. market opportunity
85M+ 4.1% U.S. screening market for Cologuard* >$14B Market share** *Exact Sciences estimate, assuming 85 million average-risk, asymptomatic people ages 50-85, revenue per test of $500-525, and 3-year interval for Cologuard, **(292,000 completed tests x 4 to annualize x 3 to account for interval) /
Slide 9: Strong Cologuard revenue growth
2014 2018 115% revenue CAGR $454-455M In the past 2 years* Gross profit per test increased 57% S&M per test decreased 30% Total OpEx per test decreased 32% Compound annual growth rate (CAGR) from 2015 through 2018 Strong Cologuard revenue growth *Total changes between 3Q16 and 3Q18
Slide 10: Impact of Cologuard
Source: based on extrapolation of findings in DeeP-C pivotal trial population to the ~1.9M screened using Cologuard since launch: Imperiale TF et al., N Engl J Med (2014) People screened since launch 1.9M Early-stage cancers detected 8,700 Pre-cancerous polyps detected 60,000 Impact of Cologuard
Slide 11: Cologuard's growing provider adoption
121K Primary care 8K Gastroenterologists 4K 14K ~147K Total providers Note: primary care providers includes family practice, internal medicine, nurse, and physician’s assistant specialties 2014 2018 OBGYNs Other 76% provider CAGR Compound annual growth rate (CAGR) from 2015 through 2018 Cologuard’s
Slide 12: 2019 Corporate Priorities
Power the Partnership Enhance Cologuard Advance Liquid Biopsy 2019 Corporate Priorities
Slide 13: 2019 Corporate Priorities
2019 Corporate Priorities »4 Power the Partnership Enhance Cologuard x Advance Liquid Biopsy
Slide 14: Pfizer is the ideal partner to promote Cologuard
Pfizer is the ideal partner to promote Cologuard
Slide 15: Expanding partnership to Pfizer's women's health team
Expanding partnership to Pfizer’s women’s health team
Slide 16: Improving access to Cologuard
Make a version of previous slide 94% Of Cologuard patients have no out-of-pocket cost* In-network contracts include: *Exact Sciences estimate based on historical patient billing and impact of recently executed network agreements Improving access to Cologuard
Slide 17: Epic partnership advantages
#1 KLAS ranked healthcare software suite Scalable IT infrastructure Ease of ordering Data access Epic partnership advantages
Slide 18: 7M expected annual lab capacity by end of 2019
7M expected annual lab capacity by end of 2019
Slide 19: Enhance Cologuard
Enhance Cologuard
Slide 20: Label expansion opportunity for ages 45-49
50-85 screened 50-85 unscreened 45-49 label expansion opportunity 45-49 average risk 50-85 average risk +19M Increase in U.S. screening market for Cologuard including 45-49 age group* +$4B Cologuard is indicated for adults 50 and older. Exact Sciences intends to pursue a label expansion for Cologuar
Slide 21: Cologuard 2.0
50-85 unscreened Cologuard 2.0 false positives cost of goods Substitute newer, more specific markers to: recurring revenue lab through-put
Slide 22: Cologuard 2.0
Cologuard 2.0 Substitute newer, more specific markers to: false positives recurring revenue cost of goods lab through-put
Slide 23: Making earlier possible
Making earlier possible
Slide 24: 10-year collaboration with Mayo Clinic
10-year collaboration with Mayo Clinic Biomarker discovery & validation Access to samples & clinical trials Leading researchers & clinicians Liquid biopsy for top 15 cancers Proven partnership
Slide 25: New cancer test development
Esophageal Stomach Pancreatic Melanoma Lymphoma New cancer test development Prostate Biomarker discovery across 15 cancers Colorectal Lung Liver Kidney Bladder Cervix Uterine Ovarian Breast
Slide 26: Exact Sciences' advantages
Multiple classes of biomarkers Proprietary DNA chemistry State-of-the-art lab FDA-approved, automated platform Regulatory expertise Commercial scale Replace image with girl from #24 Exact Sciences’ advantages
Slide 27: Liquid biopsy: a growth area for cancer diagnostics
Source: Analyst estimates Hereditary testing Diagnosis Recurrence monitoring Therapy selection Response monitoring Projected liquid biopsy market in 2030 >$13B Screening Liquid biopsy: a growth area for cancer diagnostics Exact Sciences focusing on early detection & recurrence
Slide 28: Liver cancer: America's fifth deadliest cancer
30,200 Source: American Cancer Society, Cancer Facts & Figures 2018; all figures annual Annual deaths Liver cancer: America’s fifth deadliest cancer Prostate Liver Breast Pancreatic Colorectal Lung
Slide 29: Regular liver cancer testing leads to better outcomes
6 of 10 Survive 3 years Under regular testing 3 of 10 Survive 3 years Not under regular testing Source: Kuo, YH et al., Eur J Cancer (2010) Regular liver cancer testing leads to better outcomes
Slide 30: Market opportunity in liver cancer testing
$1.5B High-risk Americans 3M *Exact Sciences estimate **Total addressable market assumes ASP of $500 and 3M tested annually * ** Market opportunity Market opportunity in liver cancer testing
Slide 31: Promising early results for liver cancer detection
Source: Kisiel JB et al., DDW (2018) Sensitivity 95% Specificity 93% Promising early results for liver cancer detection
Slide 32: Promising early results for liver cancer detection
Promising early results for liver cancer detection 95% 93% Sensitivity Specificity
Slide 33: [LOGO]
[LOGO]
Slide 34: Exact Sciences
EXACT SCIENCES